肺癌放疗心脏基部剂量与较差生存相关
该研究对1101例接受根治性放疗的肺癌患者进行高分辨率正常组织剂量分析,通过形变配准和置换检验识别与生存相关的胸部剂量敏感区域。结果显示心脏基部存在高度显著区域,该区域剂量较高与生存较差相关(p<0.001);多因素分析中该区域剂量、肿瘤体积、体能状态和淋巴结分期与生存显著相关,而心脏平均剂量、V5和V30无显著性。控制这些因素后,该区域剂量>8.5 Gy者生存较差(log-rank p<0.001,HR 1.2)。
要点
- 心脏基部存在剂量敏感区域,该区域剂量较高与肺癌患者生存较差相关(p<0.001)。
- 多因素分析中该区域剂量、肿瘤体积、体能状态和淋巴结分期与生存显著相关。
- 心脏平均剂量、V5和V30与生存无显著相关。
核心结论
- 在肺癌患者中应用该新方法首次将心脏基部识别为剂量敏感区域,该区域较高剂量与较差生存相关。
研究设计与样本
- 对1101例接受根治性放疗的肺癌患者进行高分辨率正常组织剂量分析,所有CT影像和剂量分布形变配准至参考图像。
- 按设定时间点比较生存与未生存患者的平均剂量分布,采用置换检验评估剂量差异的统计学显著性。
- 将胸部最具统计学显著性区域的剂量纳入多因素生存分析。
主要发现
- 置换检验显示心脏基部存在高度显著区域,该区域较高剂量与较差生存相关(p<0.001)。
- Cox回归多因素分析显示该区域剂量、肿瘤体积、体能状态和淋巴结分期是与生存显著相关的因素。
- 心脏平均剂量、V5和V30无显著性。
- 控制上述因素后,该区域剂量>8.5 Gy的患者生存较差(log-rank p<0.001,HR 1.2)。
关键数值与推荐
- 该区域剂量>8.5 Gy与较差生存相关(log-rank p<0.001,HR 1.2)。
- 置换检验显示心脏基部区域剂量差异高度显著(p<0.001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advances in radiotherapy (RT) have allowed an increased proportion of lung cancer patients to be treated curatively. High doses delivered to critical thoracic organs can result in excess mortality with tolerance doses poorly defined. This work presents a novel method of identifying anatomical dose-sensitive regions within the thorax. METHODS: A high-resolution, normal-tissue dosimetric analysis was performed to identify regions in the heart that correlate with poorer survival. A total of 1101 patients treated with curative-intent RT were selected and all computed tomography imaging and dose distributions were deformed to a reference. Mean dose distributions were created for patients who survived versus those who did not at a set time point. Statistical significance of dose differences was investigated with permutation testing. The dose received by the most statistically significant region of the thorax was collected in all patients and included in a multivariate survival analysis. RESULTS: The permutation testing showed a highly significant region across the base of the heart, where higher doses were associated with worse patient survival (p < 0.001). Cox-regression multivariate analysis showed region dose, tumour volume, performance status and nodal stage were significant factors associated with survival, whereas cardiac mean dose, V5 and V30 showed no significance. Survival curves, controlling for these factors, were plotted with patients receiving doses greater than 8.5 Gy to the identified region showing worse survival (log-rank p < 0.001, hazard ratio 1.2). CONCLUSION: The application of this novel methodology in lung cancer patients identifies the base of the heart as a dose-sensitive region for the first time.
引用
- McWilliam A, Kennedy J, Hodgson C, et al. Radiation dose to heart base linked with poorer survival in lung cancer patients. Eur J Cancer. 2017. PMID: 28898766. doi:10.1016/j.ejca.2017.07.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。